Lantheus Holdings, Inc. $LNTH Shares Sold by Allspring Global Investments Holdings LLC

Key Points

• Allspring Global Investments Holdings LLC cut its Lantheus stake by 89.3% in Q4, selling 87,424 shares and leaving 10,473 shares valued at about $705,000.
• Several large institutions either initiated or expanded positions (e.g., Assenagon ~$65.7M, Polaris ~$32.7M; UBS up 73.4% to 448,452 shares; William Blair up 46.7% to 574,681), and institutional investors now own 99.06% of the stock.
• Lantheus reported stronger-than-expected Q4 results (EPS $1.67 vs. $1.17 est., revenue $406.8M vs. $367.0M), set FY2026 guidance of $5.00–$5.25 EPS, and holds a MarketBeat consensus rating of "Moderate Buy" with a $86.14 target.

Allspring Global Investments Holdings LLC decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 89.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,473 shares of the medical equipment provider's stock after selling 87,424 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Lantheus were worth $705,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in LNTH. Assenagon Asset Management S.A. acquired a new stake in shares of Lantheus during the third quarter worth $65,654,000. Polaris Capital Management LLC acquired a new stake in shares of Lantheus during the third quarter worth $32,687,000. Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Lantheus during the third quarter worth $11,443,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Lantheus by 73.4% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,452 shares of the medical equipment provider's stock worth $23,001,000 after purchasing an additional 189,814 shares during the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in shares of Lantheus by 46.7% during the third quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider's stock worth $29,475,000 after purchasing an additional 183,059 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a "buy" rating and issued a $110.00 target price on shares of Lantheus in a report on Tuesday, March 17th. Citigroup reiterated an "outperform" rating on shares of Lantheus in a report on Tuesday, February 24th. JonesTrading cut Lantheus from a "buy" rating to a "hold" rating in a report on Friday, February 27th. Mizuho lifted their target price on Lantheus from $72.00 to $85.00 and gave the company an "outperform" rating in a report on Friday, February 27th. Finally, William Blair reiterated an "outperform" rating on shares of Lantheus in a report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $86.14.

Lantheus Stock Down 1.0%

Shares of Lantheus stock opened at $80.59 on Friday. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The firm has a market cap of $5.25 billion, a P/E ratio of 23.91 and a beta of -0.12. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $108.91. The business has a 50-day moving average price of $74.61 and a 200 day moving average price of $65.01.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. The firm had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.Lantheus's quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.